{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:30:21Z","timestamp":1793658621682,"version":"4.5.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031315","name":"AstraZeneca UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"AstraZeneca UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.lanepe.2023.100747","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:56:55Z","timestamp":1697158615000},"page":"100747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"special_numbering":"C","title":["Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study"],"prefix":"10.1016","volume":"35","author":[{"given":"Rachael A.","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabada","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Arnetorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9100-1575","authenticated-orcid":false,"given":"Samira","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Carty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7981-7299","authenticated-orcid":false,"given":"Nahila","family":"Justo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2093-5781","authenticated-orcid":false,"given":"Sudhir","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-4869","authenticated-orcid":false,"given":"Jennifer K.","family":"Quint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10379","key":"10.1016\/j.lanepe.2023.100747_bib1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0140-6736(22)02465-5","article-title":"Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis","volume":"401","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100747_bib2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/irv.12982","article-title":"COVID-19 severity from Omicron and Delta SARS-CoV-2 variants","volume":"16","author":"Wrenn","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"issue":"10323","key":"10.1016\/j.lanepe.2023.100747_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0140-6736(22)00017-4","article-title":"Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study","volume":"399","author":"Wolter","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2023.100747_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070695","article-title":"Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study","volume":"378","author":"Ward","year":"2022","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.lanepe.2023.100747_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cmi.2023.03.017","article-title":"Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients","volume":"29","author":"Hu","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.lanepe.2023.100747_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01012-7","article-title":"No time for complacency on COVID-19 in Europe","author":"Flahault","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100747_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41577-022-00678-4","article-title":"Milder disease with Omicron: is it the virus or the pre-existing immunity?","volume":"22","author":"Sigal","year":"2022","journal-title":"Nature Rev Immunol"},{"issue":"7902","key":"10.1016\/j.lanepe.2023.100747_bib8","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41586-022-04462-1","article-title":"Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant","volume":"603","author":"Suzuki","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.lanepe.2023.100747_bib9","article-title":"Outpatient regimens to reduce COVID-19 hospitalizations: a systematic review and meta-analysis of randomized controlled trials","author":"Sullivan","year":"2023","journal-title":"medRxiv"},{"issue":"10371","key":"10.1016\/j.lanepe.2023.100747_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0140-6736(22)02398-4","article-title":"Uptake of monoclonal antibodies and antiviral therapies for COVID-19 in Scotland","volume":"401","author":"Tibble","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.lanepe.2023.100747_bib11","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1473-3099(23)00122-6","article-title":"Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study","volume":"23","author":"Arbel","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanepe.2023.100747_bib12","series-title":"Deaths registered weekly in England and Wales, provisional","author":"Office for National Statistics","year":"2023"},{"issue":"19","key":"10.1016\/j.lanepe.2023.100747_bib16","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1001\/jama.2023.5348","article-title":"Risk of death in patients hospitalized for COVID-19 vs seasonal influenza in fall-winter 2022-2023","volume":"329","author":"Xie","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2023.100747_bib17","series-title":"Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic","author":"World Health Organization","year":"2023"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100747_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ajhp\/zxab344","article-title":"COVID-19 vaccine use in immunocompromised patients: a commentary on evidence and recommendations","volume":"79","author":"Duly","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"10.1016\/j.lanepe.2023.100747_bib19","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression","volume":"80","author":"Prendecki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lanepe.2023.100747_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101965","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19","volume":"59","author":"Shoham","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.lanepe.2023.100747_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2023.100747_bib22","article-title":"Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study","volume":"9","author":"Tartof","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"7","key":"10.1016\/j.lanepe.2023.100747_bib23","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2213-2600(22)00170-9","article-title":"Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants","volume":"10","author":"Tartof","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanepe.2023.100747_bib24","article-title":"COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada","volume":"20","author":"Bahremand","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.lanepe.2023.100747_bib25","first-page":"1","article-title":"Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study","author":"Ketkar","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.lanepe.2023.100747_bib26","series-title":"COVID-19: guidance for people whose immune system means they are at higher risk","year":"2023"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100747_bib27","first-page":"128","article-title":"Information for persons who are immunocompromised regarding prevention and treatment of SARS-CoV-2 infection in the context of currently circulating Omicron sublineages\u2013United States, January 2023","volume":"72","author":"Patel","year":"2023","journal-title":"Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100747_bib28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1192\/bjp.2022.44","article-title":"The impact of shielding during the COVID-19 pandemic on mental health: evidence from the English Longitudinal Study of Ageing","volume":"221","author":"Di Gessa","year":"2022","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.lanepe.2023.100747_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.puhe.2023.02.008","article-title":"Did the UK's public health shielding policy protect the clinically extremely vulnerable during the COVID-19 pandemic in Wales? Results of EVITE Immunity, a linked data retrospective study","volume":"218","author":"Snooks","year":"2023","journal-title":"Pub Health"},{"issue":"8","key":"10.1016\/j.lanepe.2023.100747_bib30","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3201\/eid2608.191493","article-title":"Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States","volume":"26","author":"Patel","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100747_bib31","first-page":"329","article-title":"COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients","volume":"82","author":"Belsky","year":"2021","journal-title":"J\u00a0Infect"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100747_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004086","article-title":"Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study","volume":"20","author":"Turtle","year":"2023","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100747_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1068\/a37168","article-title":"Measuring multiple deprivation at the small-area level","volume":"38","author":"Noble","year":"2006","journal-title":"Environ Plan A"},{"key":"10.1016\/j.lanepe.2023.100747_bib34","series-title":"Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report","author":"UK Department of Health & Social Care","year":"2023"},{"key":"10.1016\/j.lanepe.2023.100747_bib35","series-title":"Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination","author":"Department of Health & Social Care","year":"2021"},{"issue":"7624","key":"10.1016\/j.lanepe.2023.100747_bib36","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2023.100747_bib37","article-title":"Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patients","author":"Cheung","year":"2023","journal-title":"medRxiv"},{"issue":"10360","key":"10.1016\/j.lanepe.2023.100747_bib38","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","article-title":"Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales","volume":"400","author":"Agrawal","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.lanepe.2023.100747_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.33446","article-title":"Evaluation of risk factors for postbooster omicron COVID-19 deaths in England","volume":"5","author":"Nafilyan","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"27","key":"10.1016\/j.lanepe.2023.100747_bib40","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15585\/mmwr.mm7127a3","article-title":"Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19\u2013COVID-NET, 10 States, March 2020-February 2022","volume":"71","author":"Singson","year":"2022","journal-title":"Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.lanepe.2023.100747_bib41","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.3390\/v14122736","article-title":"Severity of COVID-19 among hospitalized patients: Omicron remains a severe threat for immunocompromised hosts","volume":"14","author":"Nevejan","year":"2022","journal-title":"Viruses"},{"issue":"42","key":"10.1016\/j.lanepe.2023.100747_bib42","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.15585\/mmwr.mm7142a4","article-title":"Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron Predominance\u2013VISION Network, 10 states, December 2021-August 2022","volume":"71","author":"Britton","year":"2022","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lanepe.2023.100747_bib43","article-title":"Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study","volume":"379","author":"Ferdinands","year":"2022","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100747_bib44","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2567.2007.02555.x","article-title":"Immunosenescence: emerging challenges for an ageing population","volume":"120","author":"Aw","year":"2007","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100747_bib45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00281-020-00824-x","article-title":"The untwining of immunosenescence and aging","volume":"42","author":"Xu","year":"2020","journal-title":"Semin Immunopathol"},{"issue":"8","key":"10.1016\/j.lanepe.2023.100747_bib46","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41564-022-01166-0","article-title":"COVID vaccination in older adults","volume":"7","author":"H\u00e4gg","year":"2022","journal-title":"Nat Microbiol"}],"updated-by":[{"DOI":"10.1016\/j.lanepe.2024.101008","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000}}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776223001667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776223001667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:57:09Z","timestamp":1763009829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776223001667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":43,"alternative-id":["S2666776223001667"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100747","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100747"}}